ISSN:
0021-9304
Keywords:
Chemistry
;
Polymer and Materials Science
Source:
Wiley InterScience Backfile Collection 1832-2000
Topics:
Medicine
,
Technology
Notes:
Recombinant human bone morphogenetic protein- (rhBMP-) can be used to enhance the repair of congenital or acquired bone pathologies when formulated in the appropriate carrier. Poly [D, L-(lactide-co-glycolide)] (PLGA) has been shown to be an effective carrier of rhBMP-. We investigated several particle sizes PLGA and several doses of rhBMP- in a rat orthotopic model. We also investigated the effects of a fibrinolytic inhibitory agent, epsilon aminocaproic acid (EACA), on the healing response. Our data indicate that higher doses of rhBMP- resulted in increased failure torque (408 ± 70 N-mm or 60% of the intact value) and higher incidence of union (100%). The induced bone in femurs treated with the smaller particle size PLGA achieved the greatest torsional stiffness and strength. The presence of rhBMP- was necessary for new bone to form, but the presence of EACA did not change these results; the use of the PLGA carrier appeared to increase bone strength and stiffness. In fact, with higher doses of rhBMP- in PLGA, the stiffness of the new bone was equal to that of intact controls (64 ± 20 N-mm/deg [intact femurs] versus 45 ± 10 N-mm/degree [medium dose in small PLGA], 61 ± 17 N-mm/degree [high dose in small PLGA], and 36 ± 11 N-mm/degree [medium dose in large PLGA]; P 〉 .05). In conclusion, PLGA implanted with rhBMP- effectively aided in healing large segmental defects in rat femurs. © 1994 John Wiley & Sons, Inc.
Additional Material:
4 Ill.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1002/jbm.820281005
Permalink
